We are very pleased to have aligned with the FDA on the path forward for our MAGNITUDE clinical trial, with measures designed ...
Bridging Nations. Accelerating Therapies for Rare Diseases Together. The organization’s 2030 vision institutionalizes ...
In recent years, mRNA in lipid nanoparticles (mRNA–LNPs) has emerged as a promising strategy for treating numerous conditions ...
CRISPR gene drives bias inheritance in pests, advancing population-level control while raising questions about resistance and ...
A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving ...
HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half ...
Scientists at Texas A&M are turning an everyday pick-me-up into a high-tech medical switch. By combining caffeine with CRISPR ...
February 25, 2026 marks one year since KJ, an infant born with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, became the world's first person to receive a personalized CRISPR-based gene ...
New Early Access Express License provides streamlined, affordable access to foundational CRISPR/Cas9 intellectual property to ...
A version of this Priestley Medal address will be presented at the American Chemical Society Spring 2026 meeting ...
Durham, North Carolina and Oxford, United Kingdom, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pairwise, a global innovator in agriculture, today ...
SOUTH SAN FRANCISCO, Calif. & MADISON, Wis.-- (BUSINESS WIRE)--Feb 18, 2026-- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results